Company Analysis
Sign in

Allogene Therapeutics, Inc. (ALLO)

Nasdaq: ALLO · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade3.7
◀ Past 3.1● Present 4.9▶ Future 3.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

18 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Allogene Therapeutics, Inc.’s names, not what it holds today.

Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 6 in 2024 and 4 in 2023
Applications published
50
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology9
Medical technology5
Pharmaceuticals3
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Allogene Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
46 published
Allogene Therapeutics, Inc. its own name
US, as the owner printed on each patent
18 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,447,178Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptorsPharmaceuticalsAllogene Therapeutics, Inc.
Sep 2, 202512,404,315Protease-activating CD45-gate CARBiotechnologyAllogene Therapeutics, Inc.
Jul 22, 202512,365,873Methods for transducing immune cellsMedical technologyAllogene Therapeutics, Inc.
May 13, 202512,295,362Formulations and processes for CAR T cell drug productsMedical technologyAllogene Therapeutics, Inc.
Feb 11, 202512,221,462Methods and compositions for dosing of allogeneic chimeric antigen receptor T cellsPharmaceuticalsAllogene Therapeutics, Inc.
Feb 4, 202512,215,347Chimeric antigen receptors with enhanced signaling and activities and uses thereofBiotechnologyAllogene Therapeutics, Inc.
Dec 10, 202412,163,169Inducible chimeric cytokine receptorsBiotechnologyAllogene Therapeutics, Inc.
Dec 10, 202412,163,153Methods of manufacturing allogeneic CAR T cellsMedical technologyAllogene Therapeutics, Inc.
Oct 1, 202412,104,188Modified caspase-9 polypeptides and methods of use thereofBiotechnologyAllogene Therapeutics, Inc.
Jul 23, 202412,043,655Constitutively active chimeric cytokine receptorsMedical technologyAllogene Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0380684FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTSMedical technologyAllogene Therapeutics, Inc.
Oct 30, 20252025/0333719INDUCIBLE CHIMERIC CYTOKINE RECEPTORSBiotechnologyAllogene Therapeutics, Inc.
Jul 17, 20252025/0230410CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED SIGNALING AND ACTIVITIES AND USES THEREOFBiotechnologyAllogene Therapeutics, Inc.
Jun 26, 20252025/0207199METHODS FOR DETECTING GENOMIC ABNORMALITIES IN CELLSBiotechnologyAllogene Therapeutics, Inc.
May 29, 20252025/0171731METHODS OF MANUFACTURING ALLOGENEIC CAR T CELLSMedical technologyAllogene Therapeutics, Inc.
Mar 13, 20252025/0084149METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSPharmaceuticalsAllogene Therapeutics, Inc.
Feb 13, 20252025/0051421CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORSMedical technologyAllogene Therapeutics, Inc.
Dec 26, 20242024/0425839MODIFIED CASPASE-9 POLYPEPTIDES AND METHODS OF USE THEREOFBiotechnologyAllogene Therapeutics, Inc.
Oct 31, 20242024/0360196INHIBITORY CHIMERIC ANTIGEN RECEPTORSBiotechnologyAllogene Therapeutics, Inc.
Aug 22, 20242024/0277763RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFPharmaceuticalsAllogene Therapeutics, Inc. · patent 12,447,178 granted from it
What it applied for, 2024 to 2025: Biotechnology 10 · Medical technology 5 · Pharmaceuticals 3 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALLO · research, not advice